Global Med Technologies(R), Inc. Announces Its First EdgeCell Cellular Therapy Software and EdgeLab/HLA Software Sale in North A
September 15 2009 - 9:00AM
PR Newswire (US)
Global Med's Inlog, S.A. Subsidiary Demonstrates its Global Reach
with Licenses to Hema Quebec in Canada DENVER, Sept. 15
/PRNewswire-FirstCall/ -- Global Med Technologies , Inc. ("Global
Med" or the "Company") (OTC:GLOB) (BULLETIN BOARD: GLOB) , an
international e-Health, medical information technology company,
today announced that its Inlog subsidiary has licensed its EdgeCell
Cellular Therapy Software and EdgeLab/HLA Laboratory Information
Management Software for Human Leukocyte Antigen matching (marketed
as "Labo Serveur" in France) to the Hema-Quebec in Quebec, Canada.
Financial terms of this significant agreement were not disclosed.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO)
Hema-Quebec will use EdgeCell in its Stem Cell Laboratory and
Public Cord Blood Bank. EdgeCell is a state-of-the-art Cellular
Therapy software solution for hospitals, surgery centers and health
care facilities. EdgeCell fully tracks the procurement process
including the medical history questionnaire, all required testing
including specimen reception and infectious disease testing,
product preparation, packaging, labeling and storage, as well as
crossmatching and distribution. EdgeCell incorporates an extensive
list of safety features along with full traceability and generation
of regulatory documentation. The complex nature of stem cell
laboratories and cord blood banks dictates that distinct business
rules and parameters be tailored to each type of product. EdgeCell
meets these needs through its ability to configure and maintain
distinct business rules and parameters for each type of product, be
it stem cells or cord blood. Inlog has the ISO 9001:2000 and
NSF/ISO 25051/12119 certification for EdgeCell, helping to assure a
high level of quality in the design, testing and validation of the
software, the documentation of the software and the quality of
support and maintenance. Hema-Quebec will utilize the Human
Leukocyte Antigen (HLA) matching capability of EdgeLab for the
complex process of HLA matching its patients for the Stem Cell
Laboratory and the Public Cord Blood Bank. Since EdgeLab was
introduced into the hospital market in 1999 as "Labo Serveur", it
has become a leading laboratory information management system in
Europe with more than 150 licensed laboratories. EdgeLab is
connected to more than 1,000 analyzers and interchanges data with
all major hospital healthcare software applications. EdgeLab can be
easily configured to meet the business needs of large, diverse,
multi-site hospital laboratories, as well as small, single-site
hospitals. It has a vibrant, easy-to-use Windows graphical
interface in addition to a comprehensive range of laboratory
functionality. Dr. Francine Decary, President and Chief Executive
Officer of Hema-Quebec, stated that "the management software
package and the expertise by Global Med Technologies is a valuable
solution that would enable Hema-Quebec to optimize our stem cell
laboratory operations and support the growth of the Public Cord
Blood Bank." Michael I. Ruxin, M.D., Chairman and Chief Executive
Officer of Global Med Technologies, Inc., stated, "We are very
proud to have been selected by Hema-Quebec as the software supplier
for their state-of-the-art Stem Cell Laboratory and Public Cord
Blood Bank. This sizable transaction is a major event for Global
Med, expanding our distribution of EdgeCell and EdgeLab into Canada
and North America." Dr. Ruxin added, "We expect that markets for
both of these products could rise substantially in North America as
demand grows for proven cellular therapy solutions. We feel we are
well positioned to answer this demand with Global Med's software
solutions that are currently being implemented successfully in
Europe and with top-notch support teams here in the United States."
Thomas F. Marcinek, President and Chief Operating Officer of Global
Med Technologies, commented, "The need for software solutions such
as EdgeCell is rapidly increasing as more hospitals enter this
emerging market. In fact, only a miniscule part of this market has
been penetrated to date. With a global target market of more than
10,000 hospitals and surgical centers, we see EdgeCell as a growth
platform that will greatly enhance our domestic and international
expansion. We are confident in this product and its ability to
provide the quality transplant management software our customers
and potential customers have been seeking. As a forerunner in this
essential technology, we are poised to satisfy the growing demand
for proven biologic transplant management systems and to grow our
global presence as a provider of quality healthcare software
solutions." About the Hema-Quebec Created in 1998, Hema-Quebec's
mission is to efficiently provide adequate quantities of safe,
optimal blood components, blood substitutes, human tissues and cord
blood to meet the needs of all Quebec residents, as well as to
provide and develop expertise, along with specialized and
innovative services and products in the fields of transfusion
medicine and human tissue transplantation. Hema-Quebec has 1,300
employees, some 2,000 blood drives and more than 300,000 blood
donors every year, 16,000 partner volunteers and more than 485,000
blood products delivered to hospitals in Quebec annually to fulfill
the needs of patients. About Global Med Technologies , Inc. Global
Med Technologies, Inc. is an international healthcare information
technology company which develops regulated and non-regulated
products and services for the healthcare industry. As a leading
provider of blood and laboratory systems and services, Global Med's
products are deployed in 20 countries and serve over 2,100
transfusion centers, blood banks and laboratory sites. Global Med's
domestic companies are Wyndgate Technologies , a leader in software
products and services for donor centers and hospital transfusion
services; eDonor , which offers web-based donor relationship
management systems; and PeopleMed(TM), Inc., which implements
cost-effective software validation, consulting and compliance
solutions to hospitals and donor centers. Global Med's European
subsidiary, Inlog, SA, is a leading developer of donor center and
transfusion management systems as well as cellular therapy
software, laboratory information systems and quality assurance
medical software systems internationally. For more information
about Global Med's products and services, please call 800-996-3428
or visit http://www.globalmedtech.com/. This news release may
include statements that constitute forward-looking statements,
usually containing the words "believe," "estimate," "project,"
"expects" or similar expressions. These statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements
inherently involve risks and uncertainties that could cause actual
results to differ materially from the forward-looking statements.
By making these forward-looking statements, the Company undertakes
no obligation to update these statements for revisions or changes
after the date of this news release.
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO
http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies,
Inc. CONTACT: Michael I. Ruxin, M.D. of Global Med Technologies,
Inc., +1-303-238-2000, ; or investors, Jeffrey Benison of Little
Gem Life Science Partners, +1- 212-334-8709, Web Site:
http://www.globalmedtech.com/
Copyright